How to Get Funding for a Healthcare Startup

Healthcare is the largest industry in the United States at $4.5 trillion annually, and it is one of the most resistant to change. Electronic health records are still clunky, prior authorizations take hours, clinical trials cost $2 billion on average, and 30% of healthcare spending is estimated to be waste. This creates massive opportunity for startups, but the path to capturing that opportunity is slow, expensive, and littered with regulatory and reimbursement hurdles that trip up founders from other industries.

Digital health funding totaled $10.7 billion in 2024, a significant decline from $29 billion in 2021 but still substantial. The market correction eliminated companies that were essentially consumer wellness apps dressed up as healthcare companies. What remains are startups solving genuine clinical problems: AI-powered diagnostic tools, remote patient monitoring platforms, prior authorization automation, and clinical trial matching. Investors have shifted from funding patient acquisition (which proved unsustainably expensive) to funding workflow efficiency and clinical outcomes that healthcare systems will pay for because they reduce costs.

The regulatory landscape determines your funding strategy more than your product does. A digital health app that does not make clinical claims (a wellness tracker, a patient engagement tool) can launch quickly with minimal regulatory burden. A Software as a Medical Device (SaMD) that provides diagnostic recommendations needs FDA clearance, which takes 6-18 months for a 510(k) pathway and 2-4 years for a De Novo or PMA pathway. Medical devices need clinical studies and manufacturing validation. Biotech therapeutics need Phase I through Phase III clinical trials costing $50M-$500M+. Each of these paths requires different amounts of capital, different types of investors, and different timelines.

Healthcare-Focused Venture Capital ($2M - $30M (seed to Series A)) VCs specializing in healthcare and life sciences, such as Andreessen Horowitz Bio, General Catalyst Health, and Oak HC/FT. These firms have clinical advisors, regulatory experts, and health system relationships on staff.

Pros:

• Deep understanding of FDA pathways, reimbursement, and clinical validation requirements
• Relationships with health systems, payers, and pharmaceutical companies
• Patient capital with longer time horizons than general tech VCs
• Can help navigate clinical study design and regulatory submissions

Cons:

• Highly competitive - top healthcare VCs see thousands of deals per year
• Due diligence process is extensive (3-6 months) with clinical and regulatory review
• Expect significant clinical evidence before investing at later stages
• May require clinical advisory board formation as a condition of investment

Government Grants (NIH SBIR/STTR) ($275K - $2M (non-dilutive)) Non-dilutive funding from the National Institutes of Health and other government agencies specifically for healthcare innovation. SBIR Phase I provides $275K for feasibility, Phase II provides $1-2M for development.

Pros:

• Zero equity dilution - grant money you never repay
• Credibility signal that the science is sound (peer reviewed)
• Can fund early research that is too risky for private investors
• Multiple agencies beyond NIH: NSF, DARPA, BARDA for relevant areas

Cons:

• Application process takes 3-6 months with low success rates (15-25%)
• Significant reporting and compliance requirements
• Grant scope may limit how you use the funds
• Slow disbursement - funds may take months to arrive after award

Health System Innovation Funds ($500K - $10M) Investment arms of major hospital systems like Providence Ventures, Kaiser Permanente Ventures, and UPMC Enterprises that invest in startups solving problems they face daily.

Pros:

• Built-in pilot customer and clinical validation site
• Deep understanding of real clinical workflows and pain points
• Credibility with other health systems as a reference customer
• Can accelerate sales cycles by providing internal champion

Cons:

• May want exclusivity or first-refusal rights
• Health system bureaucracy can slow down investment decisions
• Pilot-to-contract conversion is not guaranteed
• May prioritize their own institutional needs over your broader market vision

Strategic Pharma / MedTech Corporate Venture ($1M - $20M) Corporate venture arms of pharmaceutical and medical device companies like Johnson & Johnson Innovation, Novartis Venture Fund, and Medtronic Ventures that invest in complementary startups.

Pros:

• Potential for acquisition or licensing deal down the road
• Access to clinical trial infrastructure and regulatory expertise
• Distribution through established sales channels
• Deep pockets for follow-on funding if results are strong

Cons:

• Strategic interests may not align with your vision
• Due diligence focused on strategic fit, not just financial return
• May gain access to proprietary information that benefits their core business
• Investment decisions can be slow due to corporate governance

1. Regulatory strategy document: which FDA pathway (510(k), De Novo, PMA, or exempt) and timeline to clearance or approval
2. Clinical evidence plan: what studies are needed, design, sample size, endpoints, and cost estimates
3. Reimbursement strategy: CPT codes, payer coverage analysis, and health economic value proposition
4. HIPAA compliance documentation and security architecture for handling protected health information
5. Clinical advisory board with relevant specialists who have reviewed and endorsed your approach
6. Competitive landscape including both startup and incumbent solutions in your clinical area
7. Pilot data or letters of intent from health systems willing to test your solution

Healthcare investors evaluate startups on a fundamentally different axis than general tech investors. Clinical validity comes first: does your solution actually work, and can you prove it? For digital health, this means pilot data from real clinical settings showing measurable improvement in outcomes, efficiency, or cost. For devices and therapeutics, this means preclinical data and a credible clinical trial plan. Investors do not expect completed clinical trials at the seed stage, but they expect a clear plan with realistic timelines and budgets.

The second axis is reimbursement and business model. Healthcare is notoriously difficult to monetize because the person who uses the product (the patient), the person who prescribes it (the clinician), and the person who pays for it (the insurance company or employer) are three different entities with different incentives. Investors want to see that you understand this dynamic and have a clear answer for who pays, how much, and why they are motivated to pay. Selling directly to consumers is possible but expensive. Selling to health systems requires navigating procurement cycles of 6-18 months. Selling through insurance requires CPT codes and coverage decisions. Each path has tradeoffs and investors want to see that you have chosen one deliberately.

Pre-seed (3-6 months to close): Clinical concept validated with domain experts, regulatory pathway identified, prototype or mockup. Seed (4-8 months to close): Pilot data from 1-2 clinical sites, regulatory submission in progress or planned, clinical advisory board formed. Series A (6-14 months to close): FDA clearance obtained or imminent, multiple health system customers or contracts, reimbursement pathway validated.